AZD9550
Sponsors
AstraZeneca
Conditions
Healthy ParticipantsNon-alcoholic SteatohepatitisObesity or OverweightObesity/OverweightOverweight and Obesity
Phase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants
CompletedNCT05848440
Start: 2023-05-02End: 2023-11-13Updated: 2023-12-11
A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight
Active, not recruitingNCT06151964
Start: 2023-09-29End: 2027-03-17Updated: 2026-01-14
A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity
RecruitingNCT07013643
Start: 2025-06-04End: 2026-12-25Target: 75Updated: 2026-03-03
Phase 2
A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone
Active, not recruitingNCT06862791
Start: 2025-02-18End: 2026-05-25Updated: 2026-02-02
This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight
RecruitingNCT07017179
Start: 2025-05-20End: 2026-08-06Target: 871Updated: 2026-01-27